Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb topical DAC-0060 plus tazarotene in cutaneous basal cell carcinoma
2013-003336-72Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Sep 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of DAC-0060 and tazarotene in basal cell carcinoma (BCC), sponsored by European Institute of Oncology. Primary endpoint: Composite response. Started Sep 2013; status: completed.
02
Drugs
DAC-0060tazarotene
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2013-003336-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003336-72.